Articles tagged with Chimeric Antigen Receptors
In vivo CAR-T therapy reduces manufacturing time and cost, enabling more accessible cancer immunotherapy. The strategy also enables superior self-renewal capacity and anti-tumor persistence.
A team of researchers has developed chimeric allergen receptors that can suppress the immune system's response to common allergens, reducing or preventing asthma symptoms in mice. The technique could eventually be used to treat a wide variety of allergies in humans.
Researchers engineered HER2-specific CAR-T cells to simultaneously silence TIM-3 expression, demonstrating improved anti-tumor responses and significantly elevated lytic cytotoxicity. In vivo evaluations showed delayed tumor growth and minimized tumor burden with this strategy.
Researchers have identified a protein called cathepsin B that can prevent CAR T-cells from tearing off fragments from cancer cells, allowing them to stay active longer and fight cancer more effectively. This breakthrough could lead to improved durability and outcomes for patients with recurrent or difficult-to-treat blood cancers.
Researchers are diversifying CAR therapy to overcome limitations, exploring engineered cell platforms like NK cells, γδ T cells, and macrophages. This expansion could treat a broader range of diseases, including lupus, infection, cardiac fibrosis, and senescence-related disorders.
Researchers at the Center for Cell-Based Therapy developed a new approach to enhance CAR-NK cell cytotoxicity, combining optimized co-stimulation with reversible pharmacological control. The study showed increased tumor control in animal models, paving the way for improved cancer treatment.
Researchers at the Medical University of South Carolina are developing a new therapy for Type 1 diabetes that combines stem cell biology, immunology, and transplantation science. The goal is to restore beta cell function and insulin production in people with T1D without using immunosuppressive drugs.
St. Jude researchers developed a computational method to design tandem CARs that target two cancer-related proteins, overcoming previous challenges and function better in treating animal models of cancer. The approach demonstrated improved surface expression and anti-tumor function, clearing tumors in four out of five mice.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
A new tool called InflaMix uses machine learning to assess a patient's likely response to CAR T cell therapy by testing for inflammation biomarkers. The model was found to be associated with a high risk of treatment failure, including increased risk of death or disease relapse.
Researchers investigated how two CAR T cells kill cancer with distinct signaling domains. CD28.ζ-CAR molecules work quickly and efficiently, while 4-1BB.ζ-CAR molecules linger in lipid rafts for sustained collaborative killing of tumor cells. This study aims to design CAR molecules maximizing antitumor activity beyond B cell malignancies.
A new study found that inhibiting TBK1 increases CAR-T cell activity and makes cancer cells more susceptible to immune cell targeting. The researchers used patient-derived organotypic tumor spheroids (PDOTS) models to investigate the mechanisms of treatment resistance in solid tumors.
City of Hope researchers and collaborators have developed a new method to facilitate encoding numerous features in T cells, allowing for the simultaneous targeting of multiple tumor escape mechanisms. The 'zip-sorting' system doubles genetic information capacity, enabling improved anti-tumor activity and longer-lived T cells.
Researchers have found that loosening the grip of engineered chimeric antigen receptor (CAR) Tregs improves their function and effectiveness in treating autoimmune diseases. By adjusting the affinity of the CAR, the study shows that Tregs can suppress immune responses while reducing pro-inflammatory consequences.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Researchers found 11 cases of laryngeal edemas in patients after tisagenlecleucel infusion, with higher doses and CAR-positive cells linked to increased risk. Steroid administration showed promise in early management without affecting therapy effectiveness.
A new chimeric antigen receptor T cell (CAR-T) therapy called obe-cel has delivered promising results in treating patients with an aggressive blood cancer. The treatment reduced immune toxicity and persisted for longer in patients, overcoming two common limitations of earlier CAR-T cell therapies.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
Researchers have created a method to track genetically modified immune cells using PET scans, providing real-time insights into their behavior and persistence in solid tumors. This technology has the potential to inform personalized treatment options and optimize therapy regimens.
Researchers at University of California - San Francisco designed biological sensors that can ensure engineered cells are activated in tumor environments, making cancer therapies more effective. The new sensors, called SNIPRs, can bind to soluble molecules and alter gene expression, offering a promising approach for targeted therapies.
Researchers have developed an immunotherapy that targets glioblastoma by turning its microenvironment against it. The treatment uses CAR T-cells with a blueprint for a molecule that blocks tumor signals, allowing macrophages and microglia to support the attack on cancer cells.
A new CAR-T cell therapy targeting CD7 on leukaemia cells has shown promising results in treating T-ALL patients who have exhausted all standard treatment options. The therapy achieved complete remission in 16 out of 17 patients, with some remaining in remission for over five years.
A study published in Blood reported high response rates of 89% and complete responses of 70% among patients with relapsed or refractory multiple myeloma who received cilta-cel infusions. The results were comparable to those seen in clinical trials, suggesting the therapy's effectiveness in real-world settings.
A study published in Blood Advances found that CAR-T therapy can be administered safely and effectively on an outpatient basis in community hospitals, mitigating barriers to access. The treatment showed high efficacy rates, with 80% of patients experiencing an objective response and 54% achieving a complete response.
A new study published in Nature has found that the type 2 immune response is positively correlated with long-term cancer remission, contradicting previous theories that it promotes tumor growth. The research used samples from pioneering clinical trials and revealed a statistically significant correlation between type 2 immune factors a...
Scientists at St. Jude Children's Research Hospital identified two chemokines, CXCL8 and CXCL16, expressed by osteosarcoma that improved CAR T-cell homing. Modified cells expressing these chemokine receptors showed enhanced infiltration into tumors, leading to prolonged survival in a model of metastatic disease.
Researchers have designed a novel Co-STAR receptor that combines genetic components of four types of immune cells to recognize and fight cancer cells. In laboratory studies, the Co-STAR receptor induced a sustained anti-tumor response against human cancer cells, leading to long-lasting remissions in mouse models.
Researchers at the University of Wisconsin-Madison have developed a new method to treat cancer using T cells, which was discovered by chance. The two-step process 'metabolically priming' enhances the ability of T cells to target tumors and survive longer in the body.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
Researchers at U of T have identified two compounds, diindolylmethane and diindolylethane, produced by gut bacteria that can regulate the nuclear receptor CAR, potentially treating diseases like diabetes, fatty liver disease, and small intestine ulcerative colitis.
Researchers at Baylor College of Medicine conducted a phase I clinical trial using CAR T cells engineered to target the HER2 protein, which is overexpressed on sarcoma cells. The therapy showed safety and associated with clinical benefit, with improved CAR T expansion and persistence.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Researchers at Mass General Cancer Center presented advancements in rapid nucleic acid detection for cervical cancer screening using CRISPR technology. They also showcased improvements to CAR T cell therapy for pancreatic cancer, highlighting the importance of dynamic functional control to enhance its efficacy.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A study by UNC researchers found that a metabolic enzyme called Acetyl-CoA Carboxylase (ACC) causes T cells to store fat rather than burning it for energy in solid tumors. Inhibiting ACC expression allowed T cells to persist better in tumors, leading to potential breakthroughs in immunotherapies like CAR T-cell therapies.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
Researchers created an additional means for therapy to find and eliminate cancer cells using a small peptide, demonstrating better efficacy in lab tests and in vitro experiments. The study used computational analysis and predicted protein models to understand how structure impacts antigen recognition and therapy efficacy.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
A new CRISPR delivery method enables precise targeting of specific cell subsets in living animals, paving the way for programmable gene therapy. The system uses antibody-targeted 'enveloped delivery vehicles' to selectively edit T-cells and create CAR T-cells.
A study found that patients with refractory large B-cell lymphoma who received bendamustine before CAR T-cell therapy had a shorter progression-free survival and overall response rate compared to those who did not receive bendamustine. The use of bendamustine should be avoided in these patients when possible.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
Scientists at St. Jude Children's Research Hospital created a highly adaptable system to improve the safety and efficacy of immunotherapy for solid tumors. By adding modular chimeric cytokine receptors to CAR T cells, the therapy can target multiple types of cancer without generating significant toxicity.
Scientists at St. Jude Children's Research Hospital validated GRP78 as a promising but complex target for CAR T-cell immunotherapy. However, they discovered that some tumors trick the immune cells into expressing GRP78, turning off their own cancer-killing ability.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
A new study found that ide-cel, a CAR T-cell therapy, showed similar survival outcomes for Black and white patients with multiple myeloma. Researchers hope this finding encourages the use of ide-cel in all patients with multiple myeloma.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
Scientists from Tokyo Metropolitan University have created a new polymer that can effectively transport plasmid DNA into T-cells during CAR T-cell therapy. The polymer, called PAMAM-G2-Gu, is stable, non-toxic, and doesn't use viruses, making it a promising candidate for next-gen gene carriers.
A new approach to CAR T cell therapy has been developed by modifying T-cells with a sugar molecule and PEG coating to prevent interactions with macrophages, reducing severe side effects. This strategy offers a therapeutic window for treatment and opens up potential applications for other cellular immunotherapies.
Researchers developed a technology to rapidly screen genetic edits in immune cells, identifying a new combination that improves their effectiveness against cancers. By combining multiple genes into long DNA stretches and testing thousands of combinations, scientists discovered that different CARs can be optimized by different factors.
A new study from Yale University has found a way to reduce the 'friendly fire' effect in CAR T-cell therapy, a promising form of immunotherapy. By fusing a molecular tail onto engineered T cells, researchers can inhibit their proclivity to attack each other, allowing them to survive longer and be less exhausted.
Researchers found that CAR NK cells lose metabolic fitness when competing with tumor cells for nutrients, leading to resistance. Engineering cells with IL-15 enhances metabolic fitness and provides a longer-lasting anti-tumor response.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
Cartesian Therapeutics has successfully treated patients with generalized myasthenia gravis using an RNA CAR-T therapy. The trial demonstrated marked and long-lasting clinical improvement, with three patients achieving complete or near-complete eradication of disease symptoms.
Researchers at UCL have developed base-edited T-cells that can fight leukemia, showing promise in a NHS clinical trial. Three patients with relapsed T-cell leukaemia were treated with the cells, with one patient experiencing complete remission after just four weeks.
A Phase III trial found that axicabtagene ciloleucel (axi-cel) significantly improved overall survival and progression-free survival in patients with early relapsed or refractory large B-cell lymphoma, compared to standard therapy. The estimated four-year survival rate was 54.6% with axi-cel.
Moffitt researchers develop CAR T cells that target prostate cancer biomarker PSCA, killing cancer cells and preserving bone health. Zoledronate treatment enhances antitumor activity with minimal toxicity.
A Phase I trial of CD70-targeting CAR T cell therapy ALLO-316 demonstrates encouraging response rates and disease control rates in patients with metastatic ccRCC. The treatment had a manageable safety profile, with no cases of GVHD or ICANS observed.